It is always wise to consult with a healthcare provider, especially if you have a history of renal issues or are taking medication
For the research community, the path forward is clear
The SURPASS trial indicated a higher incidence of injection site responses than placebo, which were mild to moderate ( Gastrointestinal events were the most common treatment-emergent ADEs in several clinical trials, and most were mild to moderate in intensity ( We also identified unexpected signals, such as impaired gastric emptying (n = 181, ROR 16.60, PRR 16.57, IC 3.89, EBGM 14.81), abnormal gastrointestinal sounds (n = 37, ROR 5.28, PRR 5.27, IC 2.35, EBGM 5.11), and projectile vomiting (n = 22, ROR 8.09, PRR 8.09, IC 2.94, EBGM 7.67)
50 None of the treatments had an impact on CGM-derived low sensor glucose metrics, but acarbose and liraglutide reduced hyperglycemia and glycemic variability
This finding supports the idea that semaglutide may help manage inflammation in patients with gout